Savara’s $100M raise fueled by lung disease win

2024-06-28

临床3期临床结果上市批准

Bolstered by positive Phase III data reported earlier this week for its experimental autoimmune pulmonary alveolar proteinosis (aPAP) treatment, Savara raised a $100-million follow-on Friday through the sale of just over 26 million shares at $3.81 each.

The firm’s molgramostim nebuliser, an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF), met the primary endpoint in the IMPALA-2 study and achieved a statistically significant 6% improvement in diffusing capacity of the lungs for carbon monoxide (DLCO) versus placebo at week 24.

Savara expects to submit a regulatory application for molgramostim to the FDA in the first half of 2025. If it reaches the market, Jefferies analysts estimate that the drug will generate peak sales in the US of over $400 million.

The company’s shares were up about 7% on Friday.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构